NEUROONE MEDICAL TECHNOLOGIES CorpNMTCEarnings & Financial Report
NeuroOne Medical Technologies Corp is a medical technology company specializing in the development and commercialization of diagnostic and therapeutic neurological devices for conditions including epilepsy, movement disorders, and chronic pain. Its core products include minimally invasive cortical monitoring electrodes and neurostimulation systems, primarily serving neurology and neurosurgical care providers across North America.
NMTC Q1 FY2026 Key Financial Metrics
Revenue
$2.9M
Gross Profit
$1.6M
Operating Profit
$-1.7M
Net Profit
$-1.4M
Gross Margin
54.2%
Operating Margin
-59.0%
Net Margin
-49.7%
YoY Growth
-11.7%
EPS
$-0.03
NEUROONE MEDICAL TECHNOLOGIES Corp Q1 FY2026 Financial Summary
NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue of $2.9M (down 11.7% YoY) for Q1 FY2026, with a net profit of $-1.4M (down 180.5% YoY) (-49.7% margin). Cost of goods sold was $1.3M, operating expenses totaled $3.3M.
Key Financial Metrics
| Total Revenue | $2.9M |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | 54.2% |
| Operating Margin | -59.0% |
| Report Period | Q1 FY2026 |
NEUROONE MEDICAL TECHNOLOGIES Corp Annual Revenue by Year
NEUROONE MEDICAL TECHNOLOGIES Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.1M).
NEUROONE MEDICAL TECHNOLOGIES Corp Quarterly Revenue & Net Profit History
NEUROONE MEDICAL TECHNOLOGIES Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $2.9M | -11.7% | $-1.4M | -49.7% |
| Q4 FY2025 | $2.7M | +906.6% | $-1.6M | -59.1% |
| Q3 FY2025 | $1.7M | +105.4% | $-1.5M | -88.5% |
| Q2 FY2025 | $1.4M | +0.7% | $-2.3M | -163.8% |
| Q1 FY2025 | $3.3M | +234.9% | $1.8M | 54.5% |
| Q4 FY2024 | $272.3K | -63.3% | N/A | N/A |
| Q3 FY2024 | $825.8K | +31.1% | $-2.8M | -335.1% |
| Q2 FY2024 | $1.4M | +195.4% | $-2.9M | -207.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $825776 | $272284 | $3.3M | $1.4M | $1.7M | $2.7M | $2.9M |
| YoY Growth | 195.4% | 31.1% | -63.3% | 234.9% | 0.7% | 105.4% | 906.6% | -11.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $5.4M | $4.9M | $5.4M | $6.5M | $4.5M | $10.8M | $10.8M | $8.6M |
| Liabilities | $1.5M | $1.9M | $4.5M | $3.6M | $3.3M | $2.6M | $3.7M | $2.2M |
| Equity | $3.9M | $3.0M | $822013 | $2.9M | $1.1M | $8.2M | $7.1M | $6.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.2M | $-2.4M | $-11.0M | $208049 | $-56144 | $-1.5M | $-1.5M | $-3.1M |